Xvivo Perfusion AB (publ) (XVIPF)
Xvivo Perfusion AB (publ) Statistics
Share Statistics
Xvivo Perfusion AB (publ) has 31.5M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 31.5M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 83.18 and the forward PE ratio is null. Xvivo Perfusion AB (publ)'s PEG ratio is 1.06.
| PE Ratio | 83.18 |
| Forward PE | n/a |
| PS Ratio | 17.41 |
| Forward PS | n/a |
| PB Ratio | 6.64 |
| P/FCF Ratio | 128.69 |
| PEG Ratio | 1.06 |
Enterprise Valuation
Xvivo Perfusion AB (publ) has an Enterprise Value (EV) of 13.94B.
| EV / Sales | 16.95 |
| EV / EBITDA | 157.78 |
| EV / EBIT | 125.26 |
| EV / FCF | 125.26 |
Financial Position
The company has a current ratio of 4.58, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.58 |
| Quick Ratio | 3.3 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | 0.31 |
| Interest Coverage | -1.43 |
Financial Efficiency
Return on Equity is 7.98% and Return on Invested Capital is 3.4%.
| Return on Equity | 7.98% |
| Return on Assets | 7.17% |
| Return on Invested Capital | 3.4% |
| Revenue Per Employee | $4,261,217.62 |
| Profits Per Employee | $892,134.72 |
| Employee Count | 193 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.91 |
Taxes
| Income Tax | 27.77M |
| Effective Tax Rate | 13.89% |
Stock Price Statistics
The stock price has increased by -1.65% in the last 52 weeks. The beta is 2.08, so Xvivo Perfusion AB (publ)'s price volatility has been higher than the market average.
| Beta | 2.08 |
| 52-Week Price Change | -1.65% |
| 50-Day Moving Average | 34.6 |
| 200-Day Moving Average | 42.29 |
| Relative Strength Index (RSI) | 62.73 |
| Average Volume (20 Days) | 237 |
Income Statement
In the last 12 months, Xvivo Perfusion AB (publ) had revenue of 822.41M and earned 172.18M in profits. Earnings per share was 5.47.
| Revenue | 822.41M |
| Gross Profit | 616.41M |
| Operating Income | 88.35M |
| Net Income | 172.18M |
| EBITDA | 88.35M |
| EBIT | 201.21M |
| Earnings Per Share (EPS) | 5.47 |
Balance Sheet
The company has 415.52M in cash and 34.04M in debt, giving a net cash position of 381.48M.
| Cash & Cash Equivalents | 415.52M |
| Total Debt | 34.04M |
| Net Cash | 381.48M |
| Retained Earnings | 291.76M |
| Total Assets | 2.4B |
| Working Capital | 635.57M |
Cash Flow
In the last 12 months, operating cash flow was 111.29M and capital expenditures 0, giving a free cash flow of 111.29M.
| Operating Cash Flow | 111.29M |
| Capital Expenditures | n/a |
| Free Cash Flow | 111.29M |
| FCF Per Share | 3.53 |
Margins
Gross margin is 74.95%, with operating and profit margins of 10.74% and 20.94%.
| Gross Margin | 74.95% |
| Operating Margin | 10.74% |
| Pretax Margin | 24.31% |
| Profit Margin | 20.94% |
| EBITDA Margin | 10.74% |
| EBIT Margin | 10.74% |
| FCF Margin | 13.53% |
Dividends & Yields
XVIPF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.2% |
| FCF Yield | 0.78% |
Analyst Forecast
Currently there are no analyst rating for XVIPF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 3.51 |
| Piotroski F-Score | 5 |